Evidence map›Paper›PMID 38633512›Full record

ArticleUrology case reports2024

A case report of hereditary leiomyomatosis and renal cell carcinoma (HLRCC).

Sunao Nohara, Shotaro Nakanishi, Tomoki Matsuo, Tomoko Tamaki, Seiici Saito

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sunao NoharaDepartment of Urology University of the Ryukyus, Okinawa, 9030215, Japan.
Shotaro NakanishiDepartment of Urology University of the Ryukyus, Okinawa, 9030215, Japan.
Tomoki MatsuoDepartment of Urology University of the Ryukyus, Okinawa, 9030215, Japan.
Tomoko TamakiDepartment of Pathology University of the Ryukyus, Okinawa, 9030215, Japan.
Seiici SaitoDepartment of Urology University of the Ryukyus, Okinawa, 9030215, Japan.
University of the Ryukyus · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leiomyomatosis and renal cell carcinoma (HLRCC) are rare autosomal dominant cancer syndromes characterized by cutaneous leiomyoma, uterine leiomyoma, and renal cell carcinoma (RCC). RCC in HLRCC is an aggressive metastatic tumor that develops at a young age. Here, we report the case of a patient with HLRCC who was diagnosed after the spontaneous rupture of a renal tumor. The patient underwent cytoreductive surgery, followed by combination therapy with the immune checkpoint inhibitor (ICI) nivolumab and cabozantinib, a tyrosine kinase inhibitor (TKI); however, no improvements were achieved.

Indexed as

Cytoreductive surgeryFumarate hydrataseImmune checkpoint inhibitorLeiomyomatosisRenal cell carcinomaTyrosine kinase inhibitor

Identifiers

PMID38633512
PMCPMC11021952
OpenAlexW4394673774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.